Merck's melanoma vaccine trial shows reduced recurrence or death from skin cancer

Coverage, in order

1. 16d ago
   
   first NPR Health mainstream study

   Merck's melanoma vaccine trial shows reduced recurrence or death from skin cancer

   Merck presented its mRNA melanoma vaccine trial data at a European cancer conference this weekend. Results are promising: The vaccine reduces recurrence and death alongside an immunotherapy drug.

2. 15d ago
   
   Medical Xpress indie interview

   Q&A: Could a new melanoma vaccine change cancer treatment?

   A personalized melanoma vaccine, called intismeran, could mark a major advance in cancer treatment. Last week, pharmaceutical companies Merck and Moderna announced clinical trial results showing the vaccine, combined with immunotherapy, reduced the risk of cancer returning or death by 42% compared…

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.